AMGN

Amgen
D

AMGN

Arincen67/100B

Amgen cash flow statement 1988–2026

Amgen's free cash flow over the last twelve months was 9.58B USD: operating cash flow of 12.04B USD less 2.45B USD of capital spending. That is 24.6% of its revenue and 17.60 a share.

Operating cash flow Free cash flow

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Net income
9.39B7.71B4.09B6.72B6.55B5.89B7.26B7.84B8.39B1.98B7.72B
Depreciation and amortization
4.48B5.17B5.59B4.07B3.42B3.40B3.60B2.21B1.95B1.96B2.11B
Stock-based compensation
493.00M494.00M530.00M431.00M401.00M341.00M330.00M308.00M311.00M329.00M311.00M
Change in working capital
-1.90B-1.98B2.37B-484.00M-733.00M-1.19B-216.00M-731.00M622.00M7.91B1.00M
Change in receivables
-1.86B-2.68B441.00M-1.02B-746.00M-429.00M-427.00M-504.00M-378.00M-58.00M-214.00M
Change in inventory
1.00M886.00M2.53B491.00M-742.00M-165.00M-215.00M-66.00M-3.00M133.00M-80.00M
Change in payables
100.00M428.00M312.00M-402.00M154.00M-69.00M45.00M164.00M-143.00M424.00M-44.00M
Change in other working capital
-134.00M-616.00M-920.00M442.00M601.00M-531.00M381.00M-325.00M1.15B7.41B339.00M
Other non-cash items
171.00M-715.00M141.00M-991.00M1.28B1.28B-195.00M-186.00M386.00M334.00M32.00M
Operating cash flow
12.04B9.96B11.49B8.47B9.72B9.26B10.50B9.15B11.30B11.18B10.35B
Operating cash flow growth
-8.31%-13.33%+35.64%-12.86%+4.97%-11.77%+14.72%-19.00%+1.06%+7.95%+14.07%
Capital expenditure
-2.45B-1.86B-1.10B-1.11B-936.00M-880.00M-608.00M-618.00M-738.00M-664.00M-837.00M
Acquisitions
—-53.00M0.00-26.99B-3.73B-2.69B-3.22B-13.62B195.00M-19.00M-21.00M
Purchases of investments
—0.000.00-1.00M-2.59B-8.90B-8.48B-9.39B-18.74B-33.61B-28.09B
Sales and maturities of investments
—0.000.001.67B1.22B13.23B6.98B29.39B33.77B30.41B20.42B
Other investing
-120.00M-32.00M50.00M225.00M-12.00M-35.00M-75.00M-52.00M-145.00M-148.00M-123.00M
Investing cash flow
-2.63B-1.94B-1.05B-26.20B-6.04B733.00M-5.40B5.71B14.34B-4.02B-8.66B
Debt issued (repaid)
—-5.68B-4.26B25.68B6.62B795.00M2.46B-4.51B-1.12B71.00M3.59B
Shares issued
—0.000.000.000.000.000.000.000.000.0055.00M
Share buybacks
—0.00-200.00M0.00-6.36B-4.98B-3.49B-7.70B-17.79B-3.16B-2.97B
Dividends paid
-5.37B-5.12B-4.83B-4.56B-4.20B-4.01B-3.76B-3.51B-3.51B-3.37B-3.00B
Other financing
-145.00M-52.00M-124.00M-72.00M-103.00M-78.00M-90.00M-42.00M-68.00M-140.00M-229.00M
Financing cash flow
-5.66B-10.86B-9.42B21.05B-4.04B-8.27B-4.87B-15.77B-22.49B-6.59B-2.60B
Net change in cash
3.75B-2.84B1.03B3.32B-360.00M1.72B229.00M-908.00M3.15B559.00M-903.00M
Free cash flow
9.58B8.10B10.39B7.36B8.79B8.38B9.89B8.53B10.56B10.51B9.52B
Free cash flow growth
-16.97%-22.07%+41.24%-16.23%+4.82%-15.25%+15.90%-19.19%+0.43%+10.47%+12.92%
Free cash flow margin
24.61%22.05%31.10%26.11%33.37%32.26%38.90%36.52%44.46%46.01%41.39%
Free cash flow per share
17.6014.9419.2113.6816.2414.6316.7614.0115.8814.3012.62
Free cash flow per share growth
-17.39%-22.21%+40.46%-15.77%+11.02%-12.73%+19.64%-11.76%+11.00%+13.32%+14.72%
Owner earnings (estimate)
10.20B8.79B11.46B7.74B8.86B8.50B10.34B8.44B10.78B10.48B9.89B
Income taxes paid
—0.000.000.000.000.000.000.000.000.000.00

Figures in USD. Free cash flow is operating cash flow less capital expenditure; owner earnings take off only the spending that keeps the business as it is, not the spending to grow it (an estimate by Financial Modeling Prep). Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Amgen's cash flow

Source: Financial Modeling PrepVerified against SEC filings